Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

pimasertib (AS703026)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Day One Biopharma, EMD Serono, Sanofi

Drug class:

MEK inhibitor

Related drugs:

NRAS mutation	Melanoma	NRAS mutation	Melanoma	AS703026 Sensitive: C2 – Inclusion Criteria AS703026 Sensitive : C2	AS703026 Sensitive: C2 – Inclusion Criteria AS703026 Sensitive : C2
NRAS mutation	Cutaneous Melanoma	NRAS mutation	Cutaneous Melanoma	AS703026 Sensitive: C2 – Inclusion Criteria AS703026 Sensitive : C2	AS703026 Sensitive: C2 – Inclusion Criteria AS703026 Sensitive : C2
BRAF mutation	Melanoma	BRAF mutation	Melanoma	AS703026 Sensitive: C3 – Early Trials AS703026 Sensitive : C3	AS703026 Sensitive: C3 – Early Trials AS703026 Sensitive : C3
NRAS mutation	Non Small Cell Lung Cancer	NRAS mutation	Non Small Cell Lung Cancer	AS703026 Sensitive: D – Preclinical AS703026 Sensitive : D	AS703026 Sensitive: D – Preclinical AS703026 Sensitive : D
STEAP1 expression	Solid Tumor	STEAP1 expression	Solid Tumor	AS703026 Sensitive: D – Preclinical AS703026 Sensitive : D	AS703026 Sensitive: D – Preclinical AS703026 Sensitive : D